Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › BCRX

Biocryst Pharmaceuticals

BCRX Rare disease Lead: Approved 2 Biotech Distilled articles ↓ 18 filings & releases ↓ Cash $97.0M (Sep 30, 2026) ↓ 2 verdicts ↓ 2 timing quotes ↓
DermatologyImmunologyInfectious Disease ProteinSmall Molecule

Market cap $1.98B 257.3M shares (10-Q, Oct 30, 2026) × $7.69 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. BCX17725 Ph1 readoutby year-end 2026BCX17725 Ph1 readout, by year-end 2026, notable
  2. deucrictibant Pharvaris NDA filing1H 2027deucrictibant Pharvaris NDA filing, 1H 2027, material
  3. lonvo-z Intellia PDUFA dateMar 10, 2027lonvo-z Intellia PDUFA date, Mar 10, 2027, major
  4. deucrictibant Pharvaris PDUFA dateApr 23, 2027deucrictibant Pharvaris PDUFA date, Apr 23, 2027, major
  5. navenibart topline3Q 2027navenibart topline, 3Q 2027, thesis-defining
  6. ORLADEYO corporate update~Jul 2027ORLADEYO corporate update, ~Jul 2027, notable
  7. navenibart filingby year-end 2027navenibart filing, by year-end 2027, material
  8. ORLADEYO ANDA corporate updateDec 6, 2027ORLADEYO ANDA corporate update, Dec 6, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$97.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$278M Sep 30, 2026
Operating cash flow
$33.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$375M cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Biocryst Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-16 Watch BioCryst Pharmaceuticals (BCRX) - Scientific Deep Dive for ORLADEYO, Navenibart, and Pipeline Products Cash flows and 2035 patent floor are real, but the terminal-value question—whether ORLADEYO's oral convenience moat survives a superior oral competitor—has a dated answer arriving in 2027, and the uncertainty is not compensated at current prices.
  2. 2026-11-05 Watch UPDATE: BioCryst Pharmaceuticals (BCRX) - The Inventory Quarter Q3 headline beat was driven by a one-time CareMed stocking order masking flat underlying ORLADEYO revenue, adult capsule volume is already slipping, and neither de-risking trigger for an upgrade has fired.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)